Back to Search Start Over

Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling.

Authors :
Nakamura A
Yokoyama Y
Tanaka K
Benegiamo G
Hirayama A
Zhu Q
Kitamura N
Sugizaki T
Morimoto K
Itoh H
Fukuda S
Auwerx J
Tsubota K
Watanabe M
Source :
IScience [iScience] 2020 Sep 02; Vol. 23 (9), pp. 101522. Date of Electronic Publication: 2020 Sep 02 (Print Publication: 2020).
Publication Year :
2020

Abstract

Asperuloside (ASP) is an iridoid glycoside that is extracted from Eucommia leaves. Eucommia is used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes.<br />Competing Interests: The authors declare no competing interests.<br /> (© 2020 The Authors.)

Details

Language :
English
ISSN :
2589-0042
Volume :
23
Issue :
9
Database :
MEDLINE
Journal :
IScience
Publication Type :
Academic Journal
Accession number :
32932138
Full Text :
https://doi.org/10.1016/j.isci.2020.101522